Matching articles for "flu"
Issue 1325 · November 16, 2009
Antiviral Drugs for Influenza

Currently circulating influenza virus is almost universally pandemic 2009 influenza A H1N1, but seasonal influenza strains could also appear soon. Antiviral drugs are an important adjunct to influenza…

Med Lett Drugs Ther. 2009 Nov 16; 51(1325):89-92
Currently circulating influenza virus is almost universally pandemic 2009 influenza A H1N1, but seasonal influenza strains could also appear soon. Antiviral drugs are an important adjunct to influenza vaccination for treatment and chemoprophylaxis of both pandemic and seasonal influenza. They may, however, interfere with the efficacy of FluMist , the live-attenuated intranasal vaccine, if they are administered within 48 hours before or <2 weeks after FluMist administration. Inactivated vaccines are not affected by antiviral drug therapy.
Issue 1322 · October 5, 2009
H1N1 Vaccine for Prevention of Pandemic Influenza

The FDA has licensed 4 new monovalent vaccines for prevention of respiratory illness caused by a new influenza A H1N1 virus that appears to be derived from a swine strain. The 5th vaccine should be licensed…

Med Lett Drugs Ther. 2009 Oct 5; 51(1322):77-8
The FDA has licensed 4 new monovalent vaccines for prevention of respiratory illness caused by a new influenza A H1N1 virus that appears to be derived from a swine strain. The 5th vaccine should be licensed soon. All of these vaccines are expected to become available in October. An intranasal formulation is expected in the first week of October.
Issue 1321 · September 21, 2009
Seasonal Trivalent Influenza Vaccine for 2009-2010

Two separate influenza vaccines will be available this season: the usual seasonal trivalent vaccine and a monovalent vaccine (not yet licensed by the FDA) directed at the novel H1N1 virus currently causing…

Med Lett Drugs Ther. 2009 Sep 21; 51(1321):73-4
Two separate influenza vaccines will be available this season: the usual seasonal trivalent vaccine and a monovalent vaccine (not yet licensed by the FDA) directed at the novel H1N1 virus currently causing pandemic infection. The next issue of the Medical Letter will review the pandemic H1N1 vaccine.
Issue 1282 · March 24, 2008 Free
In Brief: Influenza Developments

Recent reports (D Kaye.Clin Infect Dis April 1, 2008;46:iii) indicate that 2 of the 3 components of this year's influenza vaccine (Med Lett Drugs Ther 2007;49:81) , the influenza B and A/H3N2 antigens, do not…

Med Lett Drugs Ther. 2008 Mar 24; 50(1282):21-4
Recent reports (D Kaye.Clin Infect Dis April 1, 2008;46:iii) indicate that 2 of the 3 components of this year's influenza vaccine (Med Lett Drugs Ther 2007;49:81) , the influenza B and A/H3N2 antigens, do not matchup well with circulating strains. The B component is probably not protective. The A/H3N2 antigen in the vaccine probably provides some protection, particularly for high-risk patients. The third component, the A/H1N1 antigen, is protective against circulating A/H1N1 influenza viruses, but these viruses, unlike previous A/H1N1 strains, are developing some resistance to oseltamivir ( Tamiflu ), particularly in Europe; in the US and Canada, about 5% of influenza A/H1N1 isolates are resistant to oseltamivir in vitro . Download U.S. English
Issue 1271 · October 8, 2007
Influenza Vaccine 2007-2008

Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications.

Med Lett Drugs Ther. 2007 Oct 8; 49(1271):81-3
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications.
Issue 1246 · October 23, 2006
Addendum: Influenza Vaccine 2006-2007

Since the publication of our article on influenza vaccine (October 9, 2006), a fourth inactivated vaccine ( FluLaval - GlaxoSmithKline) has been approved by the FDA for use in people ≥18 years old. It is…

Med Lett Drugs Ther. 2006 Oct 23; 48(1246):85
Since the publication of our article on influenza vaccine (October 9, 2006), a fourth inactivated vaccine ( FluLaval - GlaxoSmithKline) has been approved by the FDA for use in people ≥18 years old. It is sold in 5-mL multi-dose vials. Each 0.5-mL intramuscular dose contains 25 mcg of mercury.
Issue 1245 · October 9, 2006
Influenza Vaccine 2006-2007

Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications.

Med Lett Drugs Ther. 2006 Oct 9; 48(1245):81-3
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications.
Issue 47 · July 1, 2006
Adult Immunization

Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed…

Treat Guidel Med Lett. 2006 Jul; 4(47):47-54
Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed here. Immunizations for travel were reviewed in a recent issue.
Issue 1227 · January 30, 2006 Free
Update: Influenza Resistance to Amantadine and Rimantadine

Our article on Antiviral Drugs for Prophylaxis and Treatment of Influenza (Med Lett Drugs Ther 2005;47:93) mentioned possible use of amantadine ( Symmetrel , and others) and rimantadine ( Flumadine , and…

Med Lett Drugs Ther. 2006 Jan 30; 48(1227):12
Our article on Antiviral Drugs for Prophylaxis and Treatment of Influenza (Med Lett Drugs Ther 2005;47:93) mentioned possible use of amantadine ( Symmetrel , and others) and rimantadine ( Flumadine , and others), but warned that the incidence of resistance has increased substantially. The CDC recently issued a Health Alert ( www.cdc.gov ) saying that current evidence indicates that a high proportion of circulating influenza A viruses in the US are now resistant to amantadine and rimantadine and they should not be used for this indication, at least this year. Click here to go to this update article.
Issue 1222 · November 21, 2005
Antiviral Drugs for Prophylaxis and Treatment of Influenza

Antiviral prophylaxis is indicated for influenza exposures that occur before (or less than 2 weeks after) vaccination with inactivated vaccine, or in years when circulating strains differ from those included…

Med Lett Drugs Ther. 2005 Nov 21; 47(1222):93-5
Antiviral prophylaxis is indicated for influenza exposures that occur before (or less than 2 weeks after) vaccination with inactivated vaccine, or in years when circulating strains differ from those included in the vaccine. Antiviral drugs can also be used for treatment of patients who develop symptoms of influenza, regardless of vaccination status. Please see Update: Influenza Resistance to Amantadine and Rimantadine
Issue 1220 · October 24, 2005
Influenza Vaccine 2005-2006

Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications. A future issue of The Medical Letter will review drug…

Med Lett Drugs Ther. 2005 Oct 24; 47(1220):85-7
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications. A future issue of The Medical Letter will review drug prophylaxis and treatment of influenza.
Issue 1194 · October 25, 2004
Antiviral Drugs for Prophylaxis and Treatment of Influenza

Due to the unanticipated shortage in the US supply of inactivated influenza vaccine, many persons who normally would have received the vaccine will be unable to get it this year. Antiviral drugs can be used…

Med Lett Drugs Ther. 2004 Oct 25; 46(1194):85-7
Due to the unanticipated shortage in the US supply of inactivated influenza vaccine, many persons who normally would have received the vaccine will be unable to get it this year. Antiviral drugs can be used for prophylaxis of unvaccinated persons who are exposed to influenza, and for treatment of both vaccinated and unvaccinated patients who develop symptoms of the disease.
Issue 1193 · October 11, 2004
Influenza Vaccine 2004-2005

Last year influenza season began in October, peaked in December (both much earlier than usual), and was associated with severe disease, particularly in children. Much of the illness was due to a circulating…

Med Lett Drugs Ther. 2004 Oct 11; 46(1193):83-4
Last year influenza season began in October, peaked in December (both much earlier than usual), and was associated with severe disease, particularly in children. Much of the illness was due to a circulating influenza A H3N2 strain (Fujian type) that had drifted antigenically from the H3N2 strain in the vaccine. The vaccine for the 2004-05 influenza season includes A/Wyoming/3/2003 (H3N2), which is antigenically equivalent to the Fujian strain, A/New Caledonia/20/99 (H1N1), which is unchanged, and a new B strain, either B/Jiangsu/10/2003 or B/Jilin/20/2003, which are both antigenically equivalent to B/Shanghai/361/2002.
Issue 1166 · September 29, 2003
Influenza Prevention 2003-2004

Unlike the last few years there is no early-season shortage of influenza vaccine. Immunization programs for all recommended individuals can proceed. There are 2 new influenza vaccine formulations available…

Med Lett Drugs Ther. 2003 Sep 29; 45(1166):78-80
Unlike the last few years there is no early-season shortage of influenza vaccine. Immunization programs for all recommended individuals can proceed. There are 2 new influenza vaccine formulations available this year, FluMist , an intranasal vaccine and Fluzone , a pediatric formulation. Timing, indications, adverse effects, dosage and cost of the vaccines is discussed. The drugs that can be used for prophylaxis of influenza are also reviewed.
Issue 1163 · August 19, 2003
FluMist: An Intranasal Live Influenza Vaccine

FluMist (MedImmune), the first live-attenuated and first intranasally administered influenza vaccine, has been approved by the FDA to prevent influenza in healthy people 5-49 years old. Given as a nasal spray,…

Med Lett Drugs Ther. 2003 Aug 19; 45(1163):65-6
FluMist (MedImmune), the first live-attenuated and first intranasally administered influenza vaccine, has been approved by the FDA to prevent influenza in healthy people 5-49 years old. Given as a nasal spray, it stimulates immunity by viral replication in the upper respiratory tract. This vaccine apparently will be advertised directly to the public as a "needle-free" alternative to intramuscular influenza vaccine.